You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Rhinology

Partnering With Patients for Clinical Decision-Making in CRSwNP

Profs. Wytske Fokkens and Joaquim Mullol investigate the importance of partnering with patients with CRSwNP in clinical decision-making.

Joaquim Mullol
Wytske Fokkens
MD, PhD
Joaquim Mullol +1 more

Learning objectives

  • Identify ways in which HCPs can partner with patients with CRSwNP to make decisions for managing their disease
Tags
expert insightsshared decision-makingdisease controlmonitoringquality of life
MAT-US-2408267 v1.0 - P Exp. Date: 08/01/2026

About these experts

Rhinology
MD, PhD

Joaquim Mullol

Director of the Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology | Hospital Clinic, Barcelona, Spain; Professor of Research and Head of the Laboratory of Clinical and Experimental Respiratory Immunoallergy | August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain | Head of Research Group at Biomedical Research Network on Respiratory Diseases (CIBERES) | Carlos III Institute of Health, Barcelona, Spain

Rhinology
MD, PhD

Wytske Fokkens

Professor in the Department of Otorhinolaryngology | Academic Medical Center, Amsterdam, Netherlands; Director | European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA)

Related resources

Type 2 Inflammation in CRSwNP: Interactive Patient Case
Rhinology
interactivity

Type 2 Inflammation in CRSwNP: Interactive Patient Case

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

Partnering With Patients for Clinical Decision-Making in CRSwNP
Rhinology
expert video

Partnering With Patients for Clinical Decision-Making in CRSwNP

Defining Mechanisms of Anosmia in CRSwNP
Rhinology
videoanimation

Defining Mechanisms of Anosmia in CRSwNP

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Remission in CRSwNP
Rhinology
Podcast

ADVENT On Air | Remission in CRSwNP

The Pathophysiology of Type 2 Inflammation in CRSwNP
Rhinology
interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

CRSwNP: A Chronic Type 2 Inflammatory Disease
Rhinology
expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

Connecting Type 2 Inflammation to CRSwNP
Rhinology
expert video

Connecting Type 2 Inflammation to CRSwNP

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission
Rhinology
expert video

IRS-ISIAN 2024 | Evolving Perspectives in CRSwNP: From Symptom Control to Disease Remission

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region